多西他赛在老年晚期非小细胞肺癌患者中的应用价值分析

摘要

目的：分析多西他赛在老年晚期非小细胞肺癌（NSCLC）患者中的应用价值。方法选取2013年7月—2015年9月江西省肿瘤医院收治的老年晚期 NSCLC 患者182例，按照入院时间分为对照组和化疗组，每组91例。对照组患者采取常规治疗，化疗组患者采用多西他赛药物化疗。比较两组患者临床转归、随访1年及3年存活率，观察化疗组患者毒副作用发生情况。结果化疗组患者临床转归优于对照组（P ﹤0.05）。化疗组患者治疗期间出现白细胞计数减少38例，血小板计数减少28例，恶心、呕吐14例，腹泻7例，脱发69例。化疗组患者随访1年存活率高于对照组（P ﹤0.05）。两组患者随访3年存活率比较，差异无统计学意义（P ﹥0.05）。结论多西他赛可有效改善老年晚期 NSCLC 患者临床转归，提高患者1年存活率，但毒副作用较多。%Objective To analyze the application effect of docetaxel in elderly patients with advanced non - small -cell lung cancer(NSCLC). Methods A total of 182 elderly patients with NSCLC were selected in Jiangxi Provincial Tumour Hospital from July 2013 to September 2015,and they were divided into control group and treatment group according to the date of admission,each of 91 cases. Patients of control group received conventional treatment,while patients of treatment group received docetaxel. Clinical outcome,1 - year and 3 - year survival rate were compared between the two groups,and incidence of toxic and side effects of treatment group was observed. Results The clinical outcome of treatment group was statistically significantly better than that of control group(P ﹤ 0. 05). Of treatment group,38 cases occurred decreasing of white blood cell count,28 cases occurred decreasing of blood platelet count,14 cases occurred nausea and vomiting,7 cases occurred diarrhea, 69 cases occurred alopecia. The 1 - year survival rate of treatment group was statistically significantly higher than that of control group(P ﹤ 0. 05),while no statistically significant differences of 3 - year survival rate was found between the two groups(P ﹥0. 05). Conclusion Docetaxel can effectively improve the clinical outcome and 1 - year survival rate of elderly patients with NSCLC,but has relatively high risk of toxic and side effect.